SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-056380
Filing Date
2024-05-09
Accepted
2024-05-09 10:12:07
Documents
75
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q eypt-20240331.htm   iXBRL 10-Q 1567892
2 EX-10.1 eypt-ex10_1.htm EX-10.1 123629
3 EX-31.1 eypt-ex31_1.htm EX-31.1 12951
4 EX-31.2 eypt-ex31_2.htm EX-31.2 13054
5 EX-32.1 eypt-ex32_1.htm EX-32.1 5763
6 EX-32.2 eypt-ex32_2.htm EX-32.2 5912
7 GRAPHIC img178399340_0.jpg GRAPHIC 17593
  Complete submission text file 0000950170-24-056380.txt   7822958

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT eypt-20240331.xsd EX-101.SCH 1304569
78 EXTRACTED XBRL INSTANCE DOCUMENT eypt-20240331_htm.xml XML 1276885
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

IRS No.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-51122 | Film No.: 24929088
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)